The Australian Government has appointed Emeritus Professor Ian Chubb AC, FAA FTSE to lead key reforms as Chair of the Inter-Governmental Policy Reform Group (IGPRG) for health and medical research, including clinical trials.
Minister for Health and Aged Care, The Hon Mark Butler MP commenting on the selection and appointment said, “Professor Chubb has dedicated his career to improving health and medical research and education in this county and I am pleased he has agreed to share his knowledge and experience through the IGPRG.”
All Australian health ministers agreed to establish the enduring IGPRG, which will provide policy and operational oversight of the National One Stop Shop for health and medical research.
Professor Chubb spoke with Australian Health Journal about his career as Chief Scientist for Australia, personal patient experience with a clinical trial and also the consultation done to date on clinical trial and medical research reform.
The National One Stop Shop Program will transform health and medical research in Australia, by making it easier for patients, researchers and sponsors to find, conduct and participate in clinical trials and research.
It will deliver innovative treatments and improved health outcomes, increase productivity and sustainability in the health system, create jobs and help grow Australia’s innovation economy.
Minister Butler attending the MedTech23 conference hosted by The Medical Technology Association of Australia in Sydney yesterday said,
“A One Stop Shop for cutting-edge clinical trials will ensure that Australian patients and researchers are among the first to benefit from new life-changing and life-saving medicines.
I have asked my department to work with states and territories on the next phase of analysis and platform specification as a priority.“
The IGPRG will also have a key role in implementing and regulating the National Clinical Trials Governance Framework which will ensure a nationally consistent approach to clinical trials.
He has been integral to the development of the One Stop Shop to date, having already led the national consultations on the design of the program.
Representing the medical technology industry MTAA CEO Ian Burgess supported the establishment of the IGPRG and the appointment of Chair Professor Chubb. He added, “There is an opportunity to maximise the potential of clinical trials in Australia by increasing the MedTech clinical trials beyond the 394 currently underway, through the One Stop Shop Program and work of the IGPRG.”
-
Primary care remodelled
Tracey Johnson is the CEO of Inala Primary Care, a not-for-profit general practice located in Inala serving approximately 7000 patients; 4400 of whom attend clinic regularly. Inala is a suburb of Brisbane, Queensland and has a population of great cultural and linguistic diversity, with just under 40% of residents speaking English at home. It is also one of Queensland’s most socioeconomically marginalised urban areas.
Australian Health Journal spoke with Tracey on the role of Inala Primary care in reducing hospital admissions.
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
-
Being Part of the New Health Frontier
In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
